Robert Towarnicki, MS
President & CEO, SIRPant Immunotherapeutics Inc.
Robert J. Towarnicki, President & CEO has over 40 years of experience in the pharmaceutical and biotechnology industry, served as President of six biotech companies developing and commercialization of novel technologies including: small molecule pharmaceuticals; biologicals, PMA and 510k medical devices; diagnostic assays; and laboratory services. Mr. Towarnicki serves as Director, President & CEO of SIRPant Immunotherapeutics, Inc., and previously served as President & CEO of Nucleonics, Inc., an RNAi therapeutics company; Chairman, President and Chief Executive Officer of Cell Pathways, Inc. (NASDAQ: CLPA), a small molecule cancer prevention and therapeutics company; and President and Chief Operating Officer of Integra Life Sciences Corporation (NASDAQ: IART), a medical device company focused on tissue regeneration technologies. Earlier experience includes Plant Manager for Pfizer Pharmaceuticals and ten years of increasing management responsibility in parenteral operations for Merck & Co. Mr. Towarnicki earned a BS and MS in Biology from Villanova University. In addition, Mr. Towarnicki has served on the Board of Directors of multiple public and private companies as well as the Biotechnology Industry Organization (BIO) and Pennsylvania BIO.